Limina Biotechnologies

Limina Bio is a preclinical-stage biotechnology company dedicated to developing first-in-class therapeutics that target astrocytes to treat central nervous system (CNS) disorders. Based on the pioneering research of Dr. Phillip G. Haydon, the company focuses on the role of glial cells in modulating neuronal activity and brain health. Their lead programs involve small molecule modulators of the P2Y1 receptor, aimed at addressing unmet needs in epilepsy and neurodegenerative diseases like Alzheimer's. By shifting the focus from neurons to the broader tripartite synapse, Limina Bio seeks to unlock new pathways for treating complex brain conditions. The company leverages a proprietary platform to identify and validate astrocyte-specific targets that have been historically overlooked in traditional drug discovery.